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Prevalence and Risk Factors of Sleep Disordered
Breathing in Fabry disease
A Prospective Cohort Study
Daniel Franzen, MD, Nicolas Gerard, MS, Daniel J. Bratton, PhD, Annette Wons, MD,
Thomas Gaisl, MD, Noriane A. Sievi, MSc, Christian F. Clarenbach, MD,
Malcolm Kohler, MD, and Pierre A. Krayenbu¨hl, MD
Abstract: Excessive daytime sleepiness (EDS) is a frequently reported
and not well-understood symptom in patients with Fabry disease (FD).
Sleep-disordered breathing (SDB) is a possible factor. As deposition of
glycosphingolipids in the upper airway muscles is likely, we hypoth-
esized that obstructive sleep apnoea (OSA) is highly prevalent in FD and
positively associated with its severity.
All patients with FD who are followed in the Fabry cohort of the
University Hospital Zurich (n¼ 62) were asked to participate in this
prospective cohort study. Eligible patients were prospectively investi-
gated by assessing their daytime sleepiness using the Epworth Sleepi-
ness Scale (ESS), the severity of FD using the Mainz Severity Score
Index (MSSI), and by an ambulatory overnight respiratory polygraphy
between November 1, 2013, and January 31, 2015. SDB was defined as
an apnea/hypopnea index (AHI) of> 5/h.
Fifty-two patients (meanSD age 42.8 14.7 years, 33% men,
meanSDBMI 23.4 3.6 kg/m2) with a median (IQR)MSSI of 12 (5–
19) were included. Median (IQR) ESS was 6 (2–10) and 7 patients
(14%) had an ESS> 10. Thirteen patients (25%) had SDB (78%
obstructive sleep apnea, 22% central sleep apnea). In the multivariable
analysis, the age was the only statistically significant predictor of SDB
(OR 1.11, 95% CI 1.04–1.18, P¼ 0.001). ESS was associated with
depression (P< 0.001) but not AHI nor age.
This study shows that SDB, especially obstructive sleep apnea is
highly prevalent in patients with Fabry disease. However, EDS in FD
seems to be related with depression rather than SDB.
ClinicalTrials.gov (identifier: NCT01947634).
(Medicine 94(52):e2413)
Abbreviations: AHI = apnea/hypopnea index, BMI = body mass
index, CSA = central sleep apnea, CT = computed tomography,
EDS = excessive daytime sleepiness, ESS = Epworth sleepiness
score, FEV1 = forced expiratory volume in 1 s, FVC = forced vital
capacity, IQR = interquartile range, LAD = left atrial diameter,
MRI = magnet resonance imaging, MSSI = Mainz Severity Score
Index, NT-proBNP = n-terminal pro-B-type natriuretic peptide, OR
= odd’s ratio, OSA = obstructive sleep apnea, PHQ-9 = patient
health questionnaire, SD = standard deviation, SDB = sleep-
disordered breathing.
INTRODUCTION
F abry disease (FD) is an X-linked lysosomal storage diseaseleading to multiorgan dysfunction due to deposition of
glycosphingolipids in various tissues.1 Excessive daytime slee-
piness (EDS) is a frequent and early reported symptom in
patients with Fabry disease, which has a major impact on their
quality of life.2 In a cohort of 49 patients (27 men; mean age 43
years) with genetically proven Fabry disease, the prevalence of
EDS was 68% exceeding most other symptoms related to FD.2
By contrast, the prevalence of EDS in the adult European
population is 18%.3 The cause of EDS in FD is not well
understood. On one hand, chronic renal or cardiac dysfunction
irrespective of the underlying cause may lead to chronic fatigue.
However, it has been shown that chronic fatigue appears in
Fabry patients without renal or cardiac dysfunction.4 And,
fatigue must be distinguished from EDS, which is defined as
the inability to maintain wakefulness and alertness during the
major waking episodes of the day, with sleep occurring unin-
tentionally or at inappropriate times almost daily for at least 3
months,5 whereas fatigue rather refers to a subjective lack of
physical or mental energy. Eventually, patients may use terms
such as fatigue and sleepiness interchangeably, and data from
patients with sleep disorders suggest that the terms have sig-
nificant overlap.6 Sleep-disordered breathing (SDB) defined as
obstructive (OSA) or central sleep apnea/hypopnea (CSA), the
latter including Cheyne–Stokes respiration, may be the reason
or at least a major contributing factor for EDS in Fabry patients.
In this regard, in 1 case-control study of 23 patients with FD,
overnight polysomnography revealed Cheyne–Stokes respir-
ation in 22% of subjects.7 Further, brain magnetic resonance
tomography showed confluent white matter lesions including
the brain stem.7 As previous studies have demonstrated an
association between white matter lesions and SDB,8,9 some
authors suspect an association of the white matter lesions
detected in their patients and the Cheyne–Stokes respiration
most likely leading to EDS.2,7 Their conclusion is supported by
the fact that severe progressive cerebral white matter lesions are
common findings in Fabry disease, occurring early in the
disease process and worsen with time.10,11 However,
Cheyne–Stokes respiration cannot be related to cerebral white
matter lesions alone as it requires an increased circulation time,
usually caused by cardiac failure.5 Eventually, both entities can
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be present in Fabry patients. As accumulation of glycosphin-
golipids in the upper airway muscles is also likely, we hypoth-
esized that OSA is also highly prevalent in FD and is associated
with its severity.
METHODS
Subjects
All patients with genetically proven FD above the age of 18
years and who are followed in the Fabry cohort of the University
Hospital Zurich (n¼ 62) were asked to participate in the study
(Figure 1). Written informed consent was obtained from all
patients included in the study. The study was approved by
the Ethics Committee of the Canton of Zurich, Switzerland
(KEK-ZH 2013–153), and is registered at ClinicalTrials.gov
(identifier: NCT01947634). This study was conducted accord-
ing to the STROBE statement.
Study Intervention
In this cross-sectional observational study, all eligible
patients were investigated by performing an unattended sleep
study at home with 1 overnight respiratory polygraphy using an
ApneaLink plus (ResMed Ltd, Bella Vista NSW, Australia)
device. The device records 5 channels of information allowing
the differentiation between obstructive and central apneas
during sleep: the patient’s nasal respiratory flow signal, respir-
atory effort, pulse, snoring, and transcutaneous oxygen satur-
ation. It has been validated as an accurate instrument to detect
apneas/hypopneas and oxygen desaturations.12,13 The results of
the overnight examination were scored manually according to
the standard criteria of the American Academy of Sleep Medi-
cine 5 by 2 investigators (AW and TG) who were blinded to the
patients and their physical data. Apneas were defined as a
cessation of airflow lasting >10 s and hypopneas as a reduction
of airflow of at least 30% lasting>10 s, associated with a fall in
oxygen saturation of >3%.5 SDB was defined as an apnea/
hypopnea index (AHI) of>5 events/h. Examinations took place
between November 1, 2013, and January 31, 2015. The patient’s
daytime sleepiness was assessed using the German version of
the Epworth Sleepiness Scale (ESS).14,15 The ESS is a self-
administered questionnaire to quantitatively measure sleep
propensity during normal daily activities and can be helpful
to distinguish true EDS from fatigue or low energy.14 An
ESS> 10 was considered to indicate clinically relevant EDS.
The severity of FD was determined using the Mainz Severity
Score Index (MSSI). The MSSI is a clinical scoring system
considering general, neurological, cardiovascular, and renal
abnormalities, which classifies disease burden by 3 grades
(mild< 20, moderate 20–40, severe> 40).16 Specific organ
involvement of FD was defined according to MSSI.16 Central
nervous system (CNS) involvement included history of stroke or
transient ischemic attack and/or ischemic lesions on magnetic
resonance imaging (MRI) or CT. Cardiovascular involvement
was defined as clinical or echocardiographic signs of congestive
heart failure and/or increased levels of N-terminal pro-B-type
natriuretic peptide (NT-proBNP) and/or changes in cardiac
muscle thickness on echocardiography or MRI and/or valve
insufficiency. Age- and sex-specific cutoff values of NT-
proBNP were considered to indicate congestive heart failure
as the dichotomous variable. The reference values were as
follows: (males/females):< 45 years (85.8/130 ng/L); 45 to
54 years (121/249 ng/L); 55 to 64 years (210/287 ng/L). Renal
affection was present if the glomerular filtration rate was
<60 mL/min and/or there was evidence of proteinuria. Depres-
sion was assessed using the self-administered patient health
questionnaire-9 (PHQ-9), which has been found to have accep-
table diagnostic properties for detecting a depressive disorder
for cutoff scores between 8 and 11.17
Outcome Measures
The primary outcome was the prevalence of EDS and SDB,
the latter classified as OSA or CSA. The secondary outcome
was to investigate possible risk factors of SDB and ESS.
Independent variables included sex, age, body mass index
(BMI), neck circumference, CNS, cardiovascular or renal invol-
vement of Fabry disease, MSSI, ESS, forced vital capacity
(FVC), forced expiratory volume in 1 s (FEV1), left ventricular
ejection fraction (LV-EF) and left atrial diameter (LAD) on
transthoracic echocardiography, NT-proBNP, and PHQ-9.
Statistical Analysis
All statistical analyses were performed using Stata version
14 (College Station, TX: StataCorp LP). Data are summarized
as median (interquartile range [IQR]), mean standard devi-
ation (SD), or percentages as appropriate. The distribution of
continuous variables was assessed using the skew statistic and
normal quantile plots. Differences between patients with and
without SDB were assessed using x2 tests for binary outcomes
and Mann–Whitney U test or unpaired t tests for continuous
outcomes as appropriate. The individual association between
SDB and each potential risk factor listed above was initially
assessed using univariable logistic regression analysis. A multi-
variable logistic regression model using a backward selection
procedure with P value for removal of 0.1 was then used to find
independent predictors of SDB. A similar procedure using
linear regression was used to assess associations with ESS.
All tests were 2-sided with a P value <0.05 considered to
indicate statistical significance.
RESULTS
From the 62 patients in the Fabry cohort, 2 patients were
excluded because of invalid ApneaLink measurements. Another
patient was excluded because FD was not genetically proven,
and 7 patients refused to participate in the study. The remaining
52 patients were included in the study. Patient characteristics
are presented in Table 1. Seven participants had an ESS> 10
(prevalence of EDS 14%, 95% CI 4, 24%). The results of the
overnight sleep examination are displayed in Table 2.
The prevalence of SDB was 25% (95% CI 13, 37%). Of the
Fabry patients assessed for eligibility 
(n=62) 
Excluded from the study (n=8) 
- Fabry disease not genetically proven (n=1) 
- Refused to participate (n=7) 
Total recruited for overnight sleep study 
and investigation of ESS, MSSI, and 
PHQ-9 (n=54) 
Data available for analysis 
(n=52) 
Invalid ApneaLink measurements (n=2) 
FIGURE 1. Study flowchart. ESS¼ Epworth sleepiness scale;
MSSI¼Mainz Severity Score Index; PHQ-9¼patient health
questionnaire.
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13 patients with SDB (78% OSA), 6 patients (12%) had mild
SDB (AHI between 5 and 15) and 7 (13%) had moderate to
severe SDB (AHI> 15) (Figure 2).
Compared to patients with an AHI 5, subjects with SDB
presented higher age, BMI, MSSI, NT-proBNP, and LAD, and
cardiovascular involvement of FD (Table 3). ESS was com-
parable in patients with and without SDB. In univariable
analyses, age (P¼ 0.001), cardiovascular involvement of FD
(P¼ 0.01), NT-proBNP (P¼ 0.008), LAD (P¼ 0.009), and
MSSI (P¼ 0.042) were significantly associated with an
increased odds of SDB (Table 4). However, in the multivariable
regression model with backward selection only age remained.
The number of central apneas per hour during sleep was not
correlated with either LAD (r¼ 0.12; P¼ 0.44) or proBNP
(r¼0.07; P¼ 0.64). The 4 covariates which were highly
significant in the univariable analyses (age, NT-proBNP,
LAD, and cardiovascular involvement) were correlated with
each other.
Notably, AHI was not significantly associated with ESS
(P¼ 0.18). Instead, MSSI (P¼ 0.005), CNS involvement
(P< 0.001), and PHQ-9 (P< 0.001) were significantly associ-
ated with ESS in univariable regression analyses. In the multi-
variable regression analysis with backward selection, only
PHQ-9 (b¼0.5, 95%CI 0.2–0.7, P< 0.001) and CNS involve-
ment (b¼2.8, 95%CI 0.5–5.2, P¼ 0.018) were statistically
significantly associated with ESS (Table 5).
TABLE 1. Patient Characteristics
Characteristics Patients (n¼ 52)
Age, years, mean (SD) 42.8 (14.7)
Male, n (%) 17 (33)
BMI, kg/m2, mean (SD) 23.4 (3.6)
Neck circumference, cm, mean (SD) 35.4 (3.1)
CNS involvement, n (%) 41 (79)
Cardiovascular involvement, n (%) 23 (44)
Renal involvement, n (%) 10 (19)
FVC, % predicted, mean (SD) 93.6 (12.7)
FEV1, % predicted, mean (SD) 82.3 (15.6)
NT-proBNP, ng/l, median (IQR) 105 (46–364)
LV-EF, %, mean (SD) 62.5 (6.6)
LAD, cm/m2, mean (SD) 2.1 (0.4)
ESS, mean (SD) 6.3 (4.1)
MSSI, median (IQR) 12 (5–19)
ERT, n (%) 32 (61.5)
PHQ-9, median (IQR) 5 (2–8)
BMI¼ body mass index, CNS¼ central nervous system,
ERT¼ enzyme replacement therapy, ESS¼Epworth sleepiness scale,
FEV1¼ forced expiratory volume in 1 s, FVC¼ forced vital capacity,
IQR¼ interquartile range, LAD¼ left atrial diameter, LV-EF¼ left
ventricular ejection fraction, MSSI¼Mainz Severity Score Index,
NT-proBNP¼N-terminal pro-B-type natriuretic peptide, PHQ-
9¼ patient health questionnaire-9, SD¼ standard deviation.
TABLE 2. Results of the Overnight Respiratory Polygraphy
Findings Patients (n¼ 52)
Sleep study duration, h 6.1 (3.5–7.2)
Apneas, n/h 1 (0–6)
Hypopneas, n/h 1 (0–18)
Obstructive apneas, % 78 (0–82)
Central apneas, % 22 (0–50)
AHI, events/h 1 (0–18)
ODI, events/h 0.7 (0–3)
SaO2< 90%, min 0 (0–2.0)
SaO2< 90%, % of total sleep time 0 (0–0.03)
Respiratory rate, per min 16 (15–18)
Heart rate, per min 59 (53–65)
Continuous data are presented as median (IQR); categorical data are
presented as n (%).
AHI¼ apnea/hypopnea index; ODI¼ oxygen desaturation index;
SaO2¼ oxygen saturation of arterial blood.
FIGURE 2. Prevalence of sleep-disordered breathing in the Fabry
cohort (n¼52). AHI ¼ apnea/hypopnea index.
TABLE 3. Patient Characteristics Classified into Patients With-
out and With OSA
Characteristics
AHI  5
(n¼ 39)
AHI> 5
(n¼ 13) P Value
Age, years 38.2 (13.0) 56.6 (10.9) <0.001
Male 11 (28) 6 (46) 0.23
BMI, kg/m2 22.8 (3.2) 25.2 (4.3) 0.036
Neck circumference, cm 34.9 (3.0) 36.9 (3.0) 0.047
CNS involvement 31 (79) 10 (77) 0.85
Cardiovascular involvement 13 (33) 10 (77) 0.006
Renal involvement 6 (15) 4 (31) 0.22
FVC, % predicted 94.4 (13.3) 91.8 (11.5) 0.55
FEV1, % predicted 84.2 (16.3) 78.0 (13.3) 0.24
NT-proBNP, ng/L 78 (42.5–169.5) 477 (124.5–1260) 0.006
LV-EF, % 61.7 (5.9) 64.6 (8.2) 0.17
LAD, cm/m2 2.0 (0.4) 2.3 (0.4) 0.004
ESS 6.5 (4.0) 5.8 (4.7) 0.59
ESS> 10 4/38 (11%) 3/13 (23%) 0.26
MSSI 11.5 (9.8) 18.8 (11.3) 0.029
Continuous data are presented as mean ( standard deviation) or
median (IQR) as appropriate; categorical data are presented as n (%).
AHI¼ apnea/hypopnea index; BMI¼ body mass index; CNS¼ cen-
central nervous system; ESS¼Epworth sleepiness scale; FVC¼ forced
vital capacity; FEV1¼ forced expiratory volume in 1 s; LV-EF¼ left
ventricular ejection fraction; LAD¼ left atrial diameter; MSSI¼Mainz
Severity Score Index; NT-proBNP¼N-terminal pro-B-type natriuretic
peptide.
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DISCUSSION
The aim of this study was to investigate the prevalence of
SDB and EDS in a cohort of patients with genetically proven
Fabry disease. We hypothesized that sleepiness, which has been
shown to be highly prevalent in these patients,2 is possibly
induced by SDB among other reasons. Furthermore, we aimed
to detect predictors for SDB and EDS in these patients. To the
best of our knowledge, this is the first study showing such a high
prevalence of SDB, especially OSA, in patients with Fabry
disease. The prevalence of SDB in the investigated Fabry
patients (25%) was substantially higher than that in the general
adult European population, in which the reported prevalence of
SDB ranges between 3% and 19% in men and 2% and 15% in
women.18–21 Considering a matched American cohort, Peppard
et al found a prevalence of mild to severe SDB (defined as
AHI> 5) ranging between 1% and 18% in 30 to 49 years old
subjects with a BMI< 25.22 However, it has to be mentioned
that the prevalence of OSA is differing globally, depending on
the geographical region.21 Therefore, our findings may not be
generalized to other regions. In a recent study on 23 Fabry
patients performed by Duning et al, the prevalence of SDB was
22%.7 In contrast to our study, Duning et al confined SDB to
CSA with Cheyne–Stokes respiration rather than OSA, which
has been attributed to microstructural changes in the brainstem.
However, a causative relationship between these reported white
matter lesions and SDB is speculative, since all of the Fabry
patients without CSA also have analog changes on MRI.7
Furthermore, cerebral white matter has been shown to be
extensively affected in OSA patients without FD.23,24 Hypothe-
tically, the reported white matter lesions in patients with FD
could also be due to OSA, and therefore these lesions may
account for the development of CSA. According to our own
(unpublished) data, we found that 50% of Fabry patients had
cerebral white matter lesions which were consistent with the
findings reported by Reisin et al.25 However, these changes
were not significantly associated with SDB.
Only a seventh of the patients were considered to have
EDS using a threshold of ESS> 10 suggesting that ESS may not
be the adequate tool to measure sleepiness in patients with FD.
Using the ESS, the prevalence of EDS in our cohort is com-
parable to the one in the general adult European population.3 In
the multivariable analysis, only depression (PHQ-9) and CNS
involvement by FD were significantly associated with ESS.
However, at least the association of depression and ESS is not
new, as ESS is a subjective measurement with the tendency to
over-report unrefreshed sleep and daytime somnolence. Any-
way, OSA and depression have overlapping symptoms, thereby
resulting in a complex relationship.26
Generally, risk factors for OSA include obesity, upper
airway abnormalities, male sex, and age.27,28 In the present
cohort with nonobese (median BMI 23 kg/m2) and comparably
young Fabry patients with a mean age of 43 years, only age was
associated with SDB suggesting the existence of other risk
factors for SDB in FD. However, due to lack of power we
possibly have not found them. As storage of globotriaosylcer-
amide in smooth muscle cells seems to play a key role in the
pathogenesis of myocardial dysfunction and bronchial involve-
ment in FD,29,30 we hypothesized an analog mechanism in the
upper airway muscles, which may contribute to the develop-
ment of OSA. Hence, MSSI, a measure of the severity of FD,
could therefore be an indicator of this proposed mechanism.
However, MSSI was only associated with SDB in the univari-
able analysis. Interestingly, age was associated with higher
MSSI—therefore the risk of OSA may be higher in older FD
patients because of more severe disease or the prolonged
exposure to the disease. In the end, the present analysis of data
does not definitively prove this hypothesis. Another interesting
hypothesis regarding the pathogenesis of SDB in FD is REM-
sleep associated hypoventilation, which is typically seen in
patients with neuromuscular disease.31 A deposition of glyco-
sphingolipids in respiratory muscles, mainly in the diaphragm
TABLE 4. Univariable Logistic Regression Analysis of Factors
With a Possible Association With AHI>5
Characteristics OR (95% CI) P Value
Age, years 1.11 (1.04,1.18) 0.001
Gender, male 2.18 (0.60,7.96) 0.24
BMI, kg/m2 1.19 (1.00,1.42) 0.051
Neck circumference, cm 1.24 (1.00,1.55) 0.055
CNS involvement 0.86 (0.19,3.88) 0.84
Cardiovascular involvement 6.67 (1.56,28.47) 0.010
Renal involvement 2.44 (0.57,10.57) 0.23
FVC, % predicted 0.98 (0.93, 1.04) 0.54
FEV1, % predicted 0.97 (0.93,1.02) 0.23
log NT-proBNP 2.00 (1.20,3.34) 0.008
LV-EF, % 1.08 (0.97,1.21) 0.17
LAD, 0.1cm/m2 1.28 (1.06,1.53) 0.009
ESS 0.96 (0.82,1.12) 0.58
MSSI 1.07 (1.00,1.13) 0.042
AHI¼ apnea/hypopnea index, BMI¼ body mass index, CI¼ confi-
confidence interval, CNS¼ central nervous system, ESS¼Epworth
Sleepiness Scale, FEV1¼ forced expiratory volume in one second,
FVC¼ forced vital capacity, LAD¼ left atrial diameter, LV-EF¼ left
left ventricular ejection fraction, MSSI¼Mainz Severity Score Index,
NT-proBNP¼N-terminal pro-B-type natriuretic peptide.
TABLE 5. Univariable Linear Regression Analysis of Factors
With a Possible Association With ESS
Characteristics b (95% CI) P Value
Age, years 0.0 (0.1,0.1) 0.80
Gender, male 1.0 (1.4,3.5) 0.41
BMI, kg/m2 0.2 (0.5,0.1) 0.21
Neck circumference, cm 0.1 (0.3,0.5) 0.52
AHI 0.0 (0.1,0.1) 0.82
CNS involvement 4.8 (2.3,7.3) <0.001
Cardiovascular involvement 0.1 (2.4,2.3) 0.95
Renal involvement 0.6 (2.3,3.5) 0.68
FVC, % predicted 0.1 (0.2, 0.0) 0.16
FEV1, % predicted 0.1 (0.2, 0.0) 0.023
log NT-proBNP 0.3 (0.6,1.1) 0.49
LV-EF, % 0.0 (0.2,0.2) 0.99
LAD, 0.1cm/m2 1.6 (1.2,4.5) 0.25
MSSI 0.1 (0.0,0.2) 0.005
PHQ-9 0.6 (0.4,0.8) <0.001
AHI¼ apnea/hypopnea index, BMI¼ body mass index, CI¼ confi-
confidence interval, CNS¼ central nervous system, ESS¼Epworth
Sleepiness Scale, FEV1¼ forced expiratory volume in one second,
FVC¼ forced vital capacity, LAD¼ left atrial diameter, LV-EF¼ left
left ventricular ejection fraction, MSSI¼Mainz Severity Score Index,
NT-proBNP¼N-terminal pro-B-type natriuretic peptide.
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possibly results in a propensity to nocturnal hypoventilation.
Unfortunately, the overnight respiratory polygraphy instrument
used in our study is inadequate to detect hypoventilation, and
blood gases nor transcutaneous carbon dioxide were measured
for purpose of the study. Therefore, we cannot comment on this
also possible mechanism. However, FVC, which is normally
reduced in patients with a relevant neuromuscular disease, was
not associated with SDB nor ESS. And, considering the small
sample size in our study, the significance level of FEV1 is
possibly too low to represent a meaningful association
with ESS.
In univariable testing, NT-proBNP and LAD, both markers
of the hemodynamic severity of heart failure, were associated
with the presence of SDB in Fabry patients. In patients with end-
stage renal disease not confined to Fabry disease, a relationship
between left atrial size and OSA severity has been described
recently.32 In addition, left atrial size has been shown to be a
predictor of CSA in a study on 62 non-Fabry patients with
chronic heart failure.33 However, MSSI, NT-proBNP, and LAD
did not remain statistically significant in the multivariable
analysis. And, the number of central apneas was not correlated
with either LAD or proBNP. Apart from age we were not able to
identify any other independent predictors of SDB in the present
cohort of Fabry patients. This leaves the question open as to
whether a possible accumulation of glycosphingolipids is
directly responsible for the development of OSA and whether
Fabry-related organ dysfunction may also contribute. None-
theless, cardiovascular involvement of FD was also associated
with SDB in a univariable analysis. As OSA has various effects
on cardiovascular damage in the general population,34 a
possibly potentiating effect of OSA on cardiovascular morbid-
ity might also be expected in patients with FD and requires
further investigation.
There are some limitations concerning the present results,
which are primarily due to the design of a cross-sectional
study without control group. The number of participants is
likely to be too low to identify various independent predictors
of SDB. Considering the rare occurrence of Fabry disease, we
think that both issues could be addressed in a multicenter
study. Finally, SDB was not investigated using polysomno-
graphy as the gold standard for overnight sleep studies.
However, ApneaLink plus is sufficiently validated for the
purpose of diagnosing SDB excluding REM-sleep-associated
hypoventilation.12,13
CONCLUSION
This is the first study showing that SDB, especially OSA, is
highly prevalent in patients with Fabry disease. ESS was shown
to be associated with PHQ-9 and CNS involvement but not AHI.
We identified age as an independent predictor of OSA in the
present cohort, leaving the question open of whether a possible
accumulation of glycosphingolipids is the reason for the devel-
opment of OSA and whether Fabry-related cardiovascular
disease may also contribute. Although we found a significant
correlation between age and the severity of FD (MSSI), we were
not able to detect a direct association between MSSI and SDB.
However, a potentiating effect of OSA on cardiovascular
morbidity in patients with FD should be addressed in a long-
term prospective study.
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